XTL Biopharmaceuticals Ltd. received a letter from Nasdaq confirming it has regained compliance with several listing rules, including the Bid Price Rule and the Equity Rule, following its acquisition of Psyga Bio Ltd. and a subsequent equity raise. The company will be subject to a Mandatory Panel Monitor for one year starting July 20, 2026. XTL Biopharmaceuticals Ltd. is a biopharmaceutical company focused on developing and improving the lives of patients with various diseases.
